90
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer

, , , , & ORCID Icon
Pages 5615-5620 | Published online: 14 Sep 2021

References

  • Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058
  • Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi:10.1016/S1470-2045(17)30608-3
  • Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer? Int J Mol Sci. 2019;20(1):146. doi:10.3390/ijms20010146
  • Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448. doi:10.1038/s41591-018-0134-3
  • Román M, Baraibar I, López I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33. doi:10.1186/s12943-018-0789-x
  • Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41(2):153–163. doi:10.7888/juoeh.41.153
  • Jiang C, Lin X, Zhao Z. Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends Mol Med. 2019;25(11):1039–1049. doi:10.1016/j.molmed.2019.07.007
  • Hsu YC, Chang YH, Chang GC, et al. Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Med. 2019;8(5):2179–2187. doi:10.1002/cam4.2120
  • Zhao ZR, Lin YB, Ng CSH, et al. Mutation profile of resected EGFR-mutated lung adenocarcinoma by next-generation sequencing. Oncologist. 2019;24(10):1368–1374. doi:10.1634/theoncologist.2018-0567
  • Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the lung cancer mutation consortium. Cancer. 2017;123(21):4099–4105. doi:10.1002/cncr.30869
  • Ricordel C, Lespagnol A, Llamas-Gutierrez F, et al. Mutational landscape of DDR2 gene in lung squamous cell carcinoma using next-generation sequencing. Clin Lung Cancer. 2018;19(2):163–169.e4. doi:10.1016/j.cllc.2017.10.006
  • Fathi Z, Mousavi SAJ, Roudi R, Ghazi F, Deb S. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: an analysis of Iranian patients. PLoS One. 2018;13(7):e0200633. doi:10.1371/journal.pone.0200633